BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24023319)

  • 1. Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.
    Coosemans A; Vanderstraeten A; Tuyaerts S; Verschuere T; Moerman P; Berneman Z; Vergote I; Amant F; Van Gool SW
    Anticancer Res; 2013 Sep; 33(9):3855-9. PubMed ID: 24023319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.
    Coosemans A; Vanderstraeten A; Tuyaerts S; Verschuere T; Moerman P; Berneman ZN; Vergote I; Amant F; VAN Gool SW
    Anticancer Res; 2013 Dec; 33(12):5495-500. PubMed ID: 24324087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma.
    Coosemans A; Wölfl M; Berneman ZN; Van Tendeloo V; Vergote I; Amant F; Van Gool SW
    Anticancer Res; 2010 Sep; 30(9):3709-14. PubMed ID: 20944158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
    Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
    J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
    Schlienger K; Chu CS; Woo EY; Rivers PM; Toll AJ; Hudson B; Maus MV; Riley JL; Choi Y; Coukos G; Kaiser LR; Rubin SC; Levine BL; Carroll RG; June CH
    Clin Cancer Res; 2003 Apr; 9(4):1517-27. PubMed ID: 12684428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
    Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
    Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and Cryopreservation of Clinical Grade Wilms' Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy.
    Smits EL; Stein B; Nijs G; Lion E; Van Tendeloo VF; Willemen Y; Anguille S; Berneman ZN
    Methods Mol Biol; 2016; 1393():27-35. PubMed ID: 27033213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
    Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
    Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.
    Zhang W; Lu X; Cui P; Piao C; Xiao M; Liu X; Wang Y; Wu X; Liu J; Yang L
    Cancer Immunol Immunother; 2019 Jan; 68(1):121-130. PubMed ID: 30306202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium.
    Van Genechten T; De Laere M; Van den Bossche J; Stein B; De Rycke K; Deschepper C; Hazes K; Peeters R; Couttenye MM; Van De Walle K; Roelant E; Maes S; Vanden Bossche S; Dekeyzer S; Huizing M; Caluwaert K; Nijs G; Cools N; Verlooy J; Norga K; Verhulst S; Anguille S; Berneman Z; Lion E
    BMJ Open; 2024 Mar; 14(3):e077613. PubMed ID: 38503417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo depletion of CD4+CD25+ regulatory T cells enhances the antigen-specific primary and memory CTL response elicited by mature mRNA-electroporated dendritic cells.
    Van Meirvenne S; Dullaers M; Heirman C; Straetman L; Michiels A; Thielemans K
    Mol Ther; 2005 Nov; 12(5):922-32. PubMed ID: 16257383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of the WT1
    Dagvadorj N; Deuretzbacher A; Weisenberger D; Baumeister E; Trebing J; Lang I; Köchel C; Kapp M; Kapp K; Beilhack A; Hünig T; Einsele H; Wajant H; Grigoleit GU
    Cancer Immunol Immunother; 2017 Mar; 66(3):319-332. PubMed ID: 27896368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic effects of T cells induced by fusion protein 6B11-pulsed dendritic cells on ovarian carcinoma cells.
    Yang W; Feng J; Chang X; Fu T; Ye X; Zhang H; Li X; Wen H; Feng L; Tong C; Cui H
    Gynecol Oncol; 2007 Apr; 105(1):238-43. PubMed ID: 17383546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced dendritic cell antigen presentation in RNA-based immunotherapy.
    Kalady MF; Onaitis MW; Padilla KM; Emani S; Tyler DS; Pruitt SK
    J Surg Res; 2002 Jun; 105(1):17-24. PubMed ID: 12069496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering WT1-Encoding mRNA to Increase Translational Efficiency in Dendritic Cells.
    Benteyn D; Heirman C; Thielemans K; Bonehill A
    Methods Mol Biol; 2016; 1428():115-23. PubMed ID: 27236795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Induction of T cell responses against autologous ovarian cancer by anti-idiotype minibody-pulsed dendritic cells].
    Yang WL; Cui H; Feng J; Chang XH; Fu TY; Ye X; Zhang H; Li XP; Wen HW; Feng LM; Tong CR
    Ai Zheng; 2004 Dec; 23(12):1639-45. PubMed ID: 15601552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells.
    Tuyaerts S; Michiels A; Corthals J; Bonehill A; Heirman C; de Greef C; Noppe SM; Thielemans K
    Cancer Gene Ther; 2003 Sep; 10(9):696-706. PubMed ID: 12944989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients.
    Tobiásová Z; Pospísilová D; Miller AM; Minárik I; Sochorová K; Spísek R; Rob L; Bartůnková J
    Clin Immunol; 2007 Jan; 122(1):18-27. PubMed ID: 17059893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.